El Salvador’s legislature approves constitutional reform allowing indefinite presidential re-election
According to Jinse Finance, El Salvador's legislative body has approved sweeping constitutional reforms that allow for indefinite presidential re-election, effectively enabling President Nayib Bukele to remain in power beyond his current term. The Legislative Assembly of El Salvador stated that Bukele's New Ideas party and its allies passed five reform proposals by a vote of 57 to 3. These reforms also extend the presidential term from five to six years and eliminate runoff elections. Opponents warn that this move will concentrate power and threaten democratic institutions, as these changes remove long-standing term limits that have checked executive authority. New Ideas party legislator Ana Figueroa proposed ending Bukele's current term two years early so that presidential and congressional elections would be held on the same schedule. If approved, Bukele's current term would end on June 1, 2027, instead of June 1, 2029.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
